Tauriga Sciences Inc (TAUG)
0.00
USD |
OTCM |
Apr 24, 16:00
Price Chart
Key Stats
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | -- |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 100.00% |
Profile
Tauriga Sciences Inc is a revenue-generating company that operates through the development, distribution, and licensing of proprietary products as well as evaluation of potential acquisition opportunities. The firm has entered into the cannabidiol (or CBD) infused chewing gum product business. This CBD-infused chewing gum product has been branded under Tauri-Gum. The company commenced sales of Peach-Lemon and Black Currant CBG Gum. It operates in two segments: Tauri-gum division consists of all retail, wholesale, and e-commerce product sales of CBD/CBG Tauri-Gum, Tauri-Gummies, and other CBD/CBG products. Pharma segment includes research and development of the company's FDA IND application for Phase II Trial of its proposed pharmaceutical-grade version of Tauri-Gum. |
URL | https://www.taurigum.com |
Investor Relations URL | N/A |
HQ State/Province | New York |
Sector | |
Industry | |
Equity Style | Small Cap/Value |
Next Earnings Release | N/A |
Last Earnings Release | N/A |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Tauriga Sciences Inc is a revenue-generating company that operates through the development, distribution, and licensing of proprietary products as well as evaluation of potential acquisition opportunities. The firm has entered into the cannabidiol (or CBD) infused chewing gum product business. This CBD-infused chewing gum product has been branded under Tauri-Gum. The company commenced sales of Peach-Lemon and Black Currant CBG Gum. It operates in two segments: Tauri-gum division consists of all retail, wholesale, and e-commerce product sales of CBD/CBG Tauri-Gum, Tauri-Gummies, and other CBD/CBG products. Pharma segment includes research and development of the company's FDA IND application for Phase II Trial of its proposed pharmaceutical-grade version of Tauri-Gum. |
URL | https://www.taurigum.com |
Investor Relations URL | N/A |
HQ State/Province | New York |
Sector | |
Industry | |
Equity Style | Small Cap/Value |
Next Earnings Release | N/A |
Last Earnings Release | N/A |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |